Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

Prostate

Volumn 42, Issue 1, 2000, Pages 73-78

  Gupta, Sanjay ^a   Srivastava, Mayank ^a   Ahmad, Nihal ^a   Bostwick, David G ^b   Mukhtar, Hasan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTWICK LABORATORIES   (United States)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 2; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; CYCLOOXYGENASE 2; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE; PROSTATIC NEOPLASMS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033988665     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G     Document Type: Article

References (33)

1. Whittemore AS. Prostate cancer. In: Doll R, Fraumeni JF, Muir CS, editors. Cancer surveys: trends in cancer incidence and mortality. Vol. 19/20. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1994. p 309-322.
2. Landis SH, Murray T, Bolden, S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-689.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
5. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609-1620.
6. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase 2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
7. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460.
8. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-4826.
9. Zimmermann KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
10. Murata H, Kawano S, Tsuji S, Tsujii M, Sawaoka H., Kimura Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenteronl 1999;94:451-455.
11. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
12. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
13. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-994.
14. Tsujii M, Kawano S, DuBois N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
15. δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803-809.
16. Tiano H, Chulada P, Spalding J, Lee C, Loftin C, Mahler J, Morham S, Langenbach R. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Proc Am Asso Cancer Res 1997;38:1727.
17. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecobix, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
18. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
19. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992;9:383-391.
20. Chen T, Cho RW, Stork PJS, Weber MJ. Elevation of cyclin adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999;59:213-218.
21. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
22. Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids 1992;27:798-803.
23. Bairati I, Meyer F, Fradet Y, Moore L. Dietary fat and advance prostate cancer. J Urol 1998;159:1271-1275.
24. Kondo Y, Homma Y, Aso Y, Kakizoe T. Promotional effects of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. Cancer Res 1994;54:6129-6132.
25. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-1118.
26. Pandalai PK, Pilat MJ, Yamazaki K, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 1996;16:815-820.
27. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366.
28. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
29. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2 dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-1216.
30. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58: 4245-4249.
31. Kuboto T, Koshizuka K, Williamson EA, Asou H, Said JW, Hilden S, Miyoshi I, Koeffler HP. Ligand for peroxysome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352.
32. Meade EA, McIntyre TM, Zimmermann GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274:8323-8334.
33. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosome 10p, 10q and 16q in human prostate cancer. Br J Urol 1994;73:390-395.